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Abstract:
Objective: The aim of  this study is testing the value of  H-FABP in the early diagnosis of  ACS alone  or with 
routinely used  biomarkers  such as myoglobin,  CK-MB,  and cTn I in patients who  admitted  to  emergency 
department (ED)  with complaint of   chest pain and suspected acute coronary syndrome.
Material  and Methods:  This prospective  and cross-sectional  study was performed  at the Emergency De-
partment of  University hospital between June 2009 and September 2010. Patients who were admitted with chest 
pain within first 48 hours and suspected ACS were enrolled to the study. Blood samples were taken for CK-MB, 
myoglobin, cTnI and H-FABP The patients were divided into two groups (ACS and non ACS). Statistical analyse 
were used for relation of  biomarkers with diagnosis of  ACS.
Results: A 66 patients were included to the study. H-FAPB values were positive in15.2% patients. When H-FABP 
was added to routinely used biomarkers in the diagnosis of  ACS, increasing was observed in all sensitivity, specifi-
city, PPV and NPV values. However, this increase was not stastistically significant.
Conclusion: H-FABP did not provide any significant change in early diagnosis and exclusion of  ACS diagnosis 
when used either alone or combination with routinely used biomarkers
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Introduction:
Early   diagnosis  of  acute  coronary   syndrome  (ACS) 
is essential  to prevent  major complications and death. 
Routinely used biomarkers such as myoglobin, MB form 
of  creatine kinase (CK-MB) and cardiac troponin-I 
(cTn I) can be detected at least 3 hours after chest pain 
and new biomarkers are needed Recent clinical and ex-
perimental studies have suggested that  heart-type  fatty 
acid-binding  protein  (H-FABP)  is  superior  to  CK-
MB  or  cardiac troponins in early detection of  ischemic 
myocardial necrosis (1,2). H-FABP is a low molecular 
weight (14.5 kDa) protein, which contains 132 amino 
acid residues (3).  Fatty acid-binding proteins bind the 
long-chained fatty acids reversibly and noncovalently, 
facilitating the intracellular cytoplasmic transport of  the 
fatty acids, and are highly expressed in tissues with ac-
tive fatty acid metabolism such as the heart muscle (4,5). 
Its concentration in blood reaches the maximum within 
6–8 h and generally decreases within 24–36 h (6).
The aim of  this study is testing the value of  H-FABP 
in the early diagnosis of  ACS alone or with routinely 
used biomarkers such as myoglobin, CK-MB and cTn 
I in patients who admitted  to emergency  department 
(ED)  with complaint  of  chest pain and suspected acute 
coronary syndrome.
Material and Methods:
This   prospective   and   cross-sectional   study   was 
performed   at   the   Emergency Department of  Bezm-i 
Alem University between June 2009 and September 
2010 after getting approval of  ethical committee.
Patients who were admitted with chest pain within first 
48 hours and suspected ACS were  enrolled  to  the 
study.  Patients with, renal failure, suspected pulmonary 
thromboembolism,  IM injection history in the last 24 
hours and unconscious patients were excluded.
After  getting  informed   consent,  chief   complaints, 
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and  history  of   patients  were noted  and physical 
examination were done by researchers. Twelve-lead 
ECGs were taken in first 10 minutes of  admission and 
blood samples were taken from antecubital vein in first 
30 minutes  for  CK-  MB  mass,  myoglobin,  cTnI 
and  H-FABP.  Evaluation  and  the  final diagnosis of  
patients were done according to ACC/ESC guidelines.
(7,8)
The patients were divided into two groups. The pa-
tients with ST segment elevation on ECG and/or el-
evated cardiac biomarker levels were taken into group 1 
(the patients with ACS  diagnosis).  The  patients  with 
non-specific  ECG  changes  and/or  negative  cardiac 
biomarker levels were taken into group 2 (non-ACS di-
agnosis). 
The H-FABP bedside test (Cardiodetect® Rennesens 
GmbH, Berlin) used in this study is a rapid chromato-
graphic immunotest designed for qualitative determina-
tion of  H-FABP. It consists of  a sample pad (blood 
separator), a conjugate pad, a nitrocellulose membrane 
and an absorbent pad incorporated in a test card that has 
the size of  a credit card. Immobilized on the membrane 
is a test line made of  a specific capture monoclonal an-
tibody for H-FABP and a second line, acting as control, 
consisting of  anti-mouse IgG. The test is performed by 
drawing four drops of  capillary whole blood from the 
patient’s blood sample and applying them onto the test-
strip. Within 15 minuntes the H-FABP test result (two 
red lines for elevated plasma H-FABP and one red line 
for non-elevated plasma H-FABP) can be read.
Miyoglobin, CK-MB and troponin levels were meas-
ured at the laboratory of  ED with Stratus CS device of  
Dade Behring Company. Reference range for myoglob-
in: 9-82 ng/mL, CK-MB mass: 0-3,6 ng/mL,  cTnI: 
0-0.1 ng/mL (Stratus  CS Dade Behring,  Germany) 
and H- FABP: 7 ng/mL (CardioDetect quant® (Ren-
nesens GmbH, Germany)) were accepted.
Information about prognosis of  patients were taken by 
phone call three months after hospital discharge.
SPSS   15.0   (SPSS   Inc,   Chicago,   IL)   and   Med-
Calc   11.3   (MedCalc   Software, Mariakerke, Belgium) 
statistical programmes were used for statistical analy-
ses of  data. ROC curve analyse were used for relation 
of  biomarkers with diagnosis of  ACS. Chi-square test 
was  used  for  comparison   statistics.   Frequency  was 
used  for  descriptive   statistics  for categorical vari-
ables. Mean ± SD for continuous variables fit a normal 
distribution and the median and IQR for variables that 
do not meet the normal distribution were used. p <0.05 
were considered statistically significant.
Results:
Fifty two (78.8%) of  66 patients were male and fourteen 
(21.2%) were female. Mean age of  the study population 
Table 1 : Demographic Characteristics of  the Patients
 Total (n)=66 Group-I (n=36)
(with diagnosis of  ACS) Group-2 (n=30)           (without ACS)
Mean age
%95 CI                          58.80±14.06
(55.34-62.26)                          59.77±13.04
(55.36-64.19)                          57.63±15.34                (51.90-63.36)
Male 52 (78,8%)              29 (80.5%)              23 (76.7%)
Female 14 (21,2%)              7 (19,5%)              7 (23.3%)
Typical chest pain34 (51,5%)  23 (63,9%)              11 (36,7%)
Atypical chest pain32 (48,5%)  13 (36,1%)              19 (63,3%)
DM                        60  32                          28
HT                        34  21                          13
IHD                        49  27                          22
Known CAD            45  32                          13
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was 58.80±14.06  years (%95 CI 55.34-62.26, min 29-
max 88). Demographic characteristics of  the patients 
were summarized in table 1.
H-FAPB  values  were  positive  in  10  (15.2%)  patients 
and  negative  in 56  (84.8%) patients. There was statisti-
cally significant difference between group 1 and group 
2 in terms of  all biochemical markers (Table 2).
When  H-FABP  was added  to routinely used biomark-
ers  in the diagnosis  of  ACS, increasing was observed 
Table 2: Biomarker results of  groups
Group-1 (n=36)
(with diagnosis of  ACS) Group-2 (n=30)             (without ACS) p
 Median IQR Median IQR 
CK-MB 1.6 0.9-4.35 1 0.6-1.6 0.015
Myoglobin 56 35.5-103.5 34.5 28-48 0.004
cTn I 0.105 0.02-0.935 0 0-0.05 0.012
H-FABP 9 positives 1 positive 0.008
in all sensitivity, specificity, PPV and NPV values. How-
ever, this increase was not stastistically significant 
(Table 3).
AUC value of  H-FABP in the diagnosis of  ACS was 
0,61 (95%CI; 0,48 – 0,73) and cTn I was 0,51 (95%CI; 
0,52 – 0,76) (Figure 1).
H-FABP reaches the highest concentration in four 
hours after cardiac injury. H-FAPB values were positive 
in 10% (n=5) of  50 patients who admitted to the emer-
gency department within  four  hours  of   chest  pain 
and  31,3%  (n=5)  of   16  patients  who  admitted  to 
the emergency department  more than 4 hours. There 
was a stastistically  significant  difference between first 
4 hours admission and more than 4 hours admission in 
terms of  positively of  H- FABP (p<0,05).
Figure 1: ROC curve analysis of  H FAB and cTn 1 in diagnosis of  ACS
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Forty-eight  patients  (72,7%)  were  reached  by  phone 
three  months  after  hospital discharge. There was no 
mortality and morbidity 72,2% (n=26) of  group 1 and 
53,3 % (n=16) of  group 2 and 13,9% (n=5) of  group 1 
and 3,3 % (n=1) of  group 2 were died.
Discussion
Chest  pain  creates  5%  of   all  ED  admissions.  Sig-
nificant  portion  of   the  patients admitted  to  the 
emergency  department  with  chest  pain  get  diagnosis 
of   ACS.  15%  of  admissions to the ED with chest 
pain are diagnosed with ACS (9,10).  Patients are admit-
ted to the ED without chest pain (47%), pricking and 
piercing chest pain (22%), and pleuritic chest pain (6%) 
(11). In our study ACS prevalence  was high. Patients 
suspected  of  having ACS were enrolled to the study 
and ACS prevalence  was higher than literature.  Liao 
et al (12) reported that 73% (n=74) of  patients  (with 
chest pain?) received  a diagnosis  of  AMI; the mean 
age of  patients was 69.0 years, and 70% of  the study 
population was male. In our study,
54.5% of  patients who were admitted to ED with chest 
pain were diagnosed with ACS; the mean age was 59.8 
years, and 78.8% were male. Early diagnosis of  AMI 
affects mortality directly; thus, biochemical  biomarkers 
have been examined with regard to faster and more ac-
curate diagnoses of  AMI (12,13).
Several studies have shown that sensitivity and specificity 
of  H-FABP ranged from 39 to 78.5% and 78.2 – 94%, 
respectively in early diagnosis of  ACS (14-20). Orak et 
al (18) was found 98% specificity and 71% sensitivity 
different from those study. The most important cause 
of  the different results in these studies which used qual-
itative techniques is thought to be the low cut-off  levels. 
100% sensitivity and 27-38% specificity were found in 
two studies which used quantitative H-FABP measure-
ments like our study (21,22).  Results of  our study were 
consistent with literature which used quantitative  H-
FABP measurement.  In addition, PPV and NPV values 
of  our study were consistent  with 63-100% PPV and 
47-97% NPV values of  literature (21,22).
Diagnostic  accuracy (AUC) of  H- FABP ranges from 
0,65 to 0,83 in the literature (15,17).  In one study, AUC 
was determined as 0,967, but this is considered  to low 
cut-off  value (18). In our study, the AUC values were 
consistent with the results of  the literature.
Freund et al (17) found that sensitivity, specificity, PPV 
and NPV values of  troponin were 71%, 97%, 78% and 
95% respectively and these values were 80%, 85%, 46% 
and 96% for  troponin  used  together  with  H-FABP. 
Mc  Mahon  et  al  (23)  found  that  sensitivity, specifi-
city, PPV and NPV values of  troponin within first six 
hours were 67.6%, 94.3%, 66% and 95% respectively, 
and these values were 88.2%, 86.8%, 52% and 98% for 
troponin used together with H-FABP.
Sensitivity, specificity, PPV and NPV values were 67.6%, 
94.3%, 66% and 95% respectively for CK-MB, 88.2%, 
86.8%, 52% and 98% respectively for CK-MB used to-
gether with H-FABP and 88.2%, 84.9%, 48% and 98% 
respectively for CK-MB, myoglobin and H- FABP used 
together (23). In our study, H-FABP increases sensitiv-
ity, specificity, PPV and NPV values of  routinely used 
biomarkers in order to increase the likelihood of  an ac-
curate diagnosis,  but  this  increase  was  not  stastisti-
cally  significant.  In  our  study,  specificity, sensitivity, 
PPV, NPV values were lower than other studies. The 
reason of  different from literatures could be the vari-
able time elapsed from the beginning of  the pain until 
emergency department.
Okomato  (24) and Orak (18) et al concluded  that CK-
MB  is less helpfull  than H- FABP in early diagnosis of  
ACS. According to Orak et al (18) this difference was 
derived from  cut- off   value  and  method  which  used 
for  H-FABP  measurement.  Slot  et  al  (14) reported 
that H- FABP is not ideal test and has high false nega-
tivity, also is not appropriate for exclusion  of  a disease 
with  high  morbidity  and  mortality  such  as ACS. In 
our study, CK-MB and H-FABP was not superior to 
each other in early diagnosis of  ACS. In addition, spe-
cificity and PPD of  H-FABP results were better than 
cTn I results on admission.  When compared  CK-MB, 
H- FABP  did not show  significant  contribution  to 
early diagnosis  of  ACS.
Limitations
The most important limitation of  our study is the low 
number of  cases and to be a single center trial.  Ischem-
ic type chest pain was used to selection of  the patients 
and this was a limitation in terms of  homogenization. 
Quantitative measurement of  H-FABP in our study was 
the other limitation.
Conclusion
Consequently  we did not found significant change in 
early diagnosis and exclusion of  ACS diagnosis when 
used either alone or combination with routinely used 
biomarkers such as myoglobin,  CK-MB  and  cTnI. 
Further   studies   with   large   study  population   should 
be performed.
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